Weihua Wang

Weihua Wang

Auto-generated profile, based on publicly available information

Weihua Wang

Shaanxi Provincial Center for Disease Control and Prevention

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2003 in Molecular Reproduction and Development
Verified
Journal Article
Closed access
PDF file
MLMing Li
Ming Li
DZDong Zhang
Dong Zhang
YHYi Hou
Yi Hou
LJLihong Jiao
Lihong Jiao
XZXing Zheng
Xing Zheng
WWWeihua Wang
Weihua Wang

10 June 2003 in Microscopy Research and Technique
Verified
Journal Article
Closed access
PDF file
WWWeihua Wang
Weihua Wang
BDBilly N. Day
Billy N. Day
GWGuang‐Ming Wu
Guang‐Ming Wu

1 November 2002 in Fertility and Sterility
Verified
Journal Article
Closed access
WWWeihua Wang
Weihua Wang
DKDavid L Keefe
David L Keefe

9 April 2021 in International Journal of Hypertension
Verified
Journal Article
Open access
PDF file
LQLin Qiu
Lin Qiu
WWWeihua Wang
Weihua Wang
RSRina Sa
Rina Sa
FLFeng Liu
Feng Liu
Objective. To understand the prevalence and its risk factors of hypertension, diabetes mellitus, and dyslipidemia among adults aged over 18 years in Northwest China and provide data for the prevention and control of chronic diseases in Northwest China. Methods. Three waves of survey on chronic diseases and nutrition monitoring with multistage stratified cluster random sampling were conducted in 10 counties of Northwest China in 2013, 2015, and 2018, respectively. Personal information, socioeconomic status (SES), and behavioral risk factors (cigarettes smoking, alcohol consumption, diets, and physical activity) were collected by face-to-face interview. Height, weight, and blood pressure were measured, and blood glucose and serum lipid were tested. Prevalence of hypertension, diabetes, and dyslipidemia of the three waves was estimated, and multivariate logistic regression was used to analyze their risk factors. Results. The prevalence of hypertension, diabetes, and dyslipidemia was 41.59%, 11.16%, and 32.48%, respectively. Their standardized prevalence was 29.31%, 7.94%, and 31.54%. Univariate analysis showed that the prevalence of hypertension, diabetes, and dyslipidemia was significantly different among educational levels, marital status, occupation, smoking, drinking, central obesity, and BMI classification ( ). Multivariate logistic regression analysis showed that factors like male gender, central obesity, overweight, and obesity were associated with hypertension, diabetes, and dyslipidemia ( ). High BMI index is one of the risk factors of the three diseases. The odds ratio (OR) of general overweight associated with hypertension, diabetes, and dyslipidemia was 1.663, 1.206, and 1.579 compared to normal body weight, respectively. And that was 3.094, 1.565, and 2.285 for obesity. Age was one of the risk factors for hypertension and diabetes ( ). Age groups of 45–59 years and 60 years and above were more associated with hypertension than of 18–44 age group (OR45-59 group = 2.777, OR60 years and above = 6.948), similar to their association with diabetes (OR45-59 group = 2.357, OR60 years and above = 3.521). Daily smoking is associated with diabetes and dyslipidemia (OR for diabetes = 1.217, OR for dyslipidemia = 1.287) and alcohol drinking associated with hypertension and dyslipidemia (OR for hypertension = 1.014, OR fordyslipidemia = 1.034). Hypertension, diabetes, and dyslipidemia were also associated with each other ( ). The number of participants with hypertension, diabetes, and dyslipidemia accounted for 2.33% of all the participants, 15.60% for participants with hypertension and dyslipidemia, 4.58% for hypertension and diabetes, and 3.57% for diabetes and dyslipidemia, respectively. Conclusion. Factors like male, smoking, drinking, central obesity, overweight, and obesity were associated with hypertension, diabetes, and dyslipidemia in northwest China. Interventions on these risk factors and coexistence of the three diseases may help improve public health in this area.

16 June 2015 in Molecular Cytogenetics
Verified
Journal Article
Open access
PDF file
HZHaiyan Zheng
Haiyan Zheng
HJHua Jin
Hua Jin
LLLian Liu
Lian Liu
JLJianqiao Liu
Jianqiao Liu
WWWeihua Wang
Weihua Wang
Aneuploidy is a leading cause of repeat implantation failure and recurrent miscarriages. Preimplantation genetic screening (PGS) enables the assessment of the numeral and structural chromosomal errors of embryos before transfer in patients undergoing in vitro fertilization. Array comparative genomic hybridization (aCGH) has been demonstrated to be an accurate PGS method and in present thought to be the gold standard, but new technologies, such as next-generation sequencing (NGS), continue to emerge. Validation of the new comprehensive NGS-based 24-chromosome aneuploidy screening technology is still needed to determine the preclinical accuracy before it might be considered as an alternative method for human PGS. In the present study, 43 human trophectoderm (TE) biopsy samples and 5 cytogenetically characterized cell lines (Coriell Cell Repositories) were tested. The same whole genome amplified product of each sample was blindly assessed with Veriseq NGS and Agilent aCGH to identify the aneuploidy status. The result showed that the NGS identified all abnormalities identified in aCGH including the numeral chromosomal abnormalities (again or loss) in the embryo samples and the structural (partial deletion and duplication) in the Coriell cell lines. Both technologies can identify a segmental imbalance as small as 1.8 Mb in size. Among the 41 TE samples with abnormal karyotypes in this study, eight (19.5 %) samples presented as multiple chromosome abnormalities. The abnormalities occurred to almost all chromosomes, except chromosome 6, 7, 17 and Y chromosome. Given its reliability and high level of consistency with an established aCGH methodology, NGS has demonstrated a robust high-throughput methodology ready for extensive clinical application in reproductive medicine, with potential advantages of reduced costs and enhanced precision. Then, a randomized controlled clinical trial confirming its clinical effectiveness is advisable to obtain a larger sequencing dataset and more evidence for the extensive use of NGS-based PGS.

29 December 2011 in Molecular Reproduction and Development
Verified
Journal Article
Closed access
PDF file
LLLifei Li
Lifei Li
XZXuehong Zhang
Xuehong Zhang
LZLihui Zhao
Lihui Zhao
XXXuefeng Xia
Xuefeng Xia
WWWeihua Wang
Weihua Wang